The impact of equol-producing status in modifying the effect of soya isoflavones on risk factors for CHD: a systematic review of randomised controlled trials.
The impact of equol-producing status in modifying the effect of soya isoflavones on risk factors for CHD: a systematic review of randomised controlled trials.
复制标题
DOI：
10.1017/jns.2016.18
复制
发表时间：
2016
影响因子：
2.5
通讯作者：
Sekikawa A
中科院分区：
文献类型：
--
作者：
Birru RL;Ahuja V;Vishnu A;Evans RW;Miyamoto Y;Miura K;Usui T;Sekikawa A
最近的研究表明，产生雌马酚（大豆异黄酮大豆苷元的代谢物）的能力对冠状动脉健康有益。由细菌作用于人体肠道中的异黄酮产生的雌马酚，在生物学上比膳食来源的异黄酮更有效。并非所有人都是雌马激素的制造者。我们调查了膳食大豆异黄酮干预后，马酚生成状态是否与冠心病的危险因素有利相关。我们系统地回顾了评估大豆异黄酮对冠心病危险因素影响的随机对照试验（RCT），并报告了马酚的产生状态。我们检索PubMed、EMBASE、Ovid Medline和Cochrane Central Register for Controlled Trials，检索截止到2015年4月出版的文献，并手工检索参考文献来确定该RCT。提取参与者的特征和结果测量并进行定性分析。从总共1671项研究中，我们确定了42篇符合我们搜索标准的文章。在这些研究中，雌马酚对冠心病危险因素的影响主要基于二次分析，统计能力不足。尽管42项研究中有14项发现，在大豆异黄酮干预后，马酚的产生显著改善了一系列风险因素，包括胆固醇和其他脂质、炎症和血压变量，但这些结果需要进一步的研究来验证。其他28项研究主要报告了无效结果。近期作为膳食补充剂的雌马酚对冠心病及其危险因素的随机对照试验有待研究。
Recent studies suggest that the ability to produce equol, a metabolite of the soya isoflavone daidzein, is beneficial to coronary health. Equol, generated by bacterial action on isoflavones in the human gut, is biologically more potent than dietary sources of isoflavones. Not all humans are equol producers. We investigated whether equol-producing status is favourably associated with risk factors for CHD following an intervention by dietary soya isoflavones. We systematically reviewed randomised controlled trials (RCT) that evaluated the effect of soya isoflavones on risk factors for CHD and that reported equol-producing status. We searched PubMed, EMBASE, Ovid Medline and the Cochrane Central Register for Controlled Trials published up to April 2015 and hand-searched bibliographies to identify the RCT. Characteristics of participants and outcomes measurements were extracted and qualitatively analysed. From a total of 1671 studies, we identified forty-two articles that satisfied our search criteria. The effects of equol on risk factors for CHD were mainly based on secondary analyses in these studies, thus with inadequate statistical power. Although fourteen out of the forty-two studies found that equol production after a soya isoflavone intervention significantly improved a range of risk factors including cholesterol and other lipids, inflammation and blood pressure variables, these results need further verification by sufficiently powered studies. The other twenty-eight studies primarily reported null results. RCT of equol, which has recently become available as a dietary supplement, on CHD and its risk factors are awaited.